|
2025
|
Invention
|
Protease-cleavable substrates and methods of use thereof.
Isolated polypeptides that include a c... |
|
2024
|
Invention
|
Protease-resistant systems for polypeptide display and methods of making and using thereof.
The ... |
|
|
Invention
|
Method of using an anti-epidermal growth factor receptor (egfr) activatable antibody to detect th... |
|
|
Invention
|
Activatable cytokine constructs and related compositions and methods.
Provided herein are activa... |
|
|
Invention
|
Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods... |
|
|
P/S
|
Pharmaceutical and veterinary products as well as sanitary products for medical purposes; diagnos... |
|
|
Invention
|
Compositions and methods for conjugating activatable antibodies.
The invention relates generally... |
|
|
Invention
|
Masking polypeptides, activatable cytokine constructs, and related compositions and methods. Prov... |
|
|
Invention
|
Activatable cytokine constructs and related compositions and methods. Provided herein are activat... |
|
|
Invention
|
Activatable cytokine constructs and combination methods.
Provided herein are methods of treating... |
|
2023
|
Invention
|
Modified antibody compositions, methods of making and using thereof.
The present disclosure prov... |
|
|
Invention
|
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof.
Th... |
|
|
Invention
|
Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use... |
|
|
P/S
|
diagnostic agents, preparations, and substances for medical purposes |
|
|
Invention
|
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies ... |
|
|
Invention
|
Compositions and methods for detecting protease activity in biological systems.
The invention re... |
|
|
Invention
|
Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof.
The... |
|
|
Invention
|
Bispecific anti-cd3 antibodies, bispecific activatable anti-cd3 antibodies, and methods of using ... |
|
|
Invention
|
Protease-cleavable moieties and methods of use thereof. Isolated polypeptides that include a clea... |
|
|
Invention
|
Protease-cleavable substrates and methods of use thereof. Isolated polypeptides that include a cl... |
|
|
Invention
|
Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof.
The invent... |
|
|
Invention
|
Epcam immunoconjugates and uses thereof. The disclosure generally relates to immunoconjugates com... |
|
|
Invention
|
Masked activatable cytokine constructs and related compositions and method.
Provided herein are ... |
|
|
Invention
|
Anti-cd71 activatable antibody drug conjugates and methods of use thereof.
The invention relates... |
|
|
Invention
|
Cd3-binding proteins and methods of use thereof.
The present disclosure includes target-binding ... |
|
|
Invention
|
Activatable multispecific molecules and methods of use thereof.
Activatable proteins comprising ... |
|
|
Invention
|
Cd3-binding proteins and methods of use thereof. The present disclosure includes target-binding p... |
|
|
Invention
|
Activatable multispecific molecules and methods of use thereof. Activatable proteins comprising a... |
|
|
Invention
|
Activatable dual-anchored masked molecules and methods of use thereof. Provided herein are activa... |
|
|
Invention
|
Activatable antigen-binding protein constructs and uses of the same. Provided herein are protease... |
|
2022
|
Invention
|
Proproteins and methods of use thereof.
A proprotein containing a functional protein coupled to ... |
|
|
Invention
|
Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use ther... |
|
|
Invention
|
Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex.
The present di... |
|
|
Invention
|
Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex. The present dis... |
|
|
Invention
|
Activatable polypeptide complex.
The present disclosure relates to activatable anti-EGFR, anti-C... |
|
|
Invention
|
Activatable polypeptide complex.
The present disclosure relates to activatable heteromultimeric ... |
|
|
Invention
|
Activatable polypeptide complex. The present disclosure relates to activatable anti-EGFR, anti-CD... |
|
|
Invention
|
Activatable polypeptide complex. The present disclosure relates to activatable heteromultimeric b... |
|
|
Invention
|
Trimeric activatable cytokine constructs and related compositions and methods.
Provided herein a... |
|
|
Invention
|
Trimeric activatable cytokine constructs and related compositions and methods. Provided herein ar... |
|
|
Invention
|
Activatable cytokine constructs and combination methods. Provided herein are methods of treating ... |
|
|
Invention
|
Method for determining protease activity in a biological sample.
A method of determining proteas... |
|
2019
|
P/S
|
Pharmaceutical preparations for the treatment of cancer. |
|
|
P/S
|
Pharmaceutical preparations. |
|
2017
|
P/S
|
Biochemicals for scientific, laboratory, and research use,
namely, proteolytically-activatable, ... |
|
|
P/S
|
Biochemicals for scientific, laboratory, and research use, namely, proteolytically-activatable, p... |
|
|
P/S
|
Biochemicals, namely, proteolytically-activatable, protease-activatable, or proteolytically activ... |
|
|
P/S
|
Biochemicals for scientific, laboratory, and research use,
namely, proteolytically- activatable,... |
|
|
P/S
|
Biological drugs for use in treating cancer [ , and autoimmunity ] ; therapeutic [ and medical di... |
|
2015
|
P/S
|
Therapeutic [ and diagnostic ] agents and preparations consisting primarily of biochemicals, immu... |
